Clinical Trials on Bone Marrow Failure Disorders in Netherlands

Total 264 results

European Society for Blood and Marrow Transplantation
Novartis; Pfizer

Completed

hATG+CsA vs hATG+CsA+Eltrombopag for SAA (RACE)

Severe Aplastic Anemia

Switzerland, Netherlands, France, Italy, Spain, United Kingdom
European Society for Blood and Marrow Transplantation
CHUGAI sanofi-aventis

Terminated

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) (SAA-G-CSF)

Aplastic Anaemia

France, Netherlands, Germany, United Kingdom, Switzerland, Italy, Sweden, Greece, Czechia
Zimmer Biomet

Completed

Subchondroplasty Procedure in Patients With Bone Marrow Lesions

Bone Marrow Edema | Bone Marrow Lesions

Germany, Netherlands, Italy, Spain, United Kingdom
Leiden University Medical Center

Unknown

The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones (OPTIMAL)

Bone Metastasis

Netherlands
UMC Utrecht

Recruiting

Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort (PRESENT)

Bone Metastases

Netherlands
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
UMC Utrecht
Isala

Completed

Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis (PRE-FURTHER)

Quality of Life | Pain | Neoplasm Metastasis | Bone Cancer | Bone Metastases | Tumor | Radiation Toxicity | Bone Neoplasm | Bone Lesion | Cancer Induced Bone Pain

Netherlands
UMC Utrecht

Completed

Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study (VERTICAL)

Bone Metastases | Spinal Metastases

Netherlands
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
Stichting Hemato-Oncologie voor Volwassenen Nederland
CTI BioPharma; Dutch Cancer Society

Active, not recruiting

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF)

Myelofibrosis

Netherlands, Belgium
UMC Utrecht
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009

Bone Metastases

Netherlands
Copenhagen University Hospital at Herlev

Unknown

A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

Polycythemia Vera | Essential Thrombocythemia

Sweden, United Kingdom, Denmark, Netherlands
Sanquin Research & Blood Bank Divisions
Netherlands: Ministry of Health, Welfare and Sports

Withdrawn

Transfusion Effects in Myelodysplastic Patients: Limiting Exposure

Myelodysplastic Syndromes

Netherlands
UMC Utrecht
Turku University Hospital; University of Bologna; University of Roma La Sapienza and other collaborators

Recruiting

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases (FURTHER)

Quality of Life | Pain | Neoplasm Metastasis | Bone Cancer | Bone Metastases | Tumor | Bone Neoplasm | Bone Lesion | Cancer Induced Bone Pain

Netherlands, Germany, Finland, Italy
Novartis Pharmaceuticals

Completed

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Myelofibrosis

United Kingdom, Germany, Canada, Singapore, Netherlands, Italy, Australia, France
Academisch Medisch Centrum - Universiteit van Amsterdam...
Netherlands Organisation for Scientific Research

Recruiting

Effect of Nocturnal Parenteral Nutrition on Bone Turnover and Energy Metabolism (NutriSync)

Osteoporosis | Insulin Sensitivity | Intestinal Failure

Netherlands
Radboud University Medical Center

Completed

Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life

Neoplasms | Telemedicine | Chronic Myeloid Leukemia | Patient Portals

Netherlands
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Protagonist Therapeutics, Inc.

Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

Polycythemia Vera

United States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Radboud University Medical Center

Completed

Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease (ANIDULAPK)

Leukemia | Leukemia, Myeloid, Acute | Myelodysplastic Syndrome

Netherlands
Radboud University Medical Center

Terminated

T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation

Lymphoma | Leukemia, Myeloid | Myelodysplastic Syndrome | Leukemia, Lymphocytic | Leukemia, Myeloid, Chronic

Netherlands
Radboud University Medical Center

Completed

The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PREPARE)

Paroxysmal Nocturnal Hemoglobinuria | Eculizumab | PK-PD

Netherlands
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Zuyderland Medisch Centrum
Maastricht University Medical Center

Completed

Adjacent Segment Disease After Anterior Cervical Decompression Surgery (ASDafterACDF)

Degenerative Disc Disease | Cervical Radiculopathy | Cervical Myelopathy | Adjacent Segment Disease

Netherlands
Rijnstate Hospital

Completed

Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting (BMD&BIG)

Disorder of Bone Density and Structure, Unspecified | Satisfaction

Netherlands
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Amedica Corporation

Completed

Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome (CASCADE)

Myelopathy | Radiating Pain | Cervicobrachial Syndrome

Netherlands
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
UMC Utrecht
Prothya Biosolutions

Terminated

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture (CAESAR)

Sepsis | Inflammation | Trauma | Multiple Organ Dysfunction Syndrome

Netherlands
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Incyte Corporation

Completed

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States, Netherlands, Austria
Henrik Endeman
Franciscus Gasthuis; Maasstad Hospital

Recruiting

Effect of HFNO Therapy on Respiratory Effort After Extubation (T-REX)

Respiratory Failure | Post Extubation Acute Respiratory Failure Requiring Reintubation

Netherlands
AKARI Therapeutics
Radboud University Medical Center

Completed

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Paroxysmal Nocturnal Haemoglobinuria (PNH)

Netherlands
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Leukemia

Netherlands, Belgium
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
Wageningen University
Erasmus Medical Center; Amsterdam UMC, location VUmc; ZonMw: The Netherlands... and other collaborators

Unknown

Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People (B-PROOF)

Osteoporosis | Cognitive Decline

Netherlands
Capturin Distribution B.V.
Radboud University Medical Center; FrieslandCampina; Rijnstate Hospital; Fonds... and other collaborators

Recruiting

Rickets Device - Feasibility Study

Rickets

Netherlands
Genzyme, a Sanofi Company

Terminated

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome (RISE)

Myelodysplastic Syndrome (MDS)

Germany, United Kingdom, France, Netherlands
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Patient Reported Outcomes in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Iraq, Germany, Austria, Italy, Taiwan, Greece, Netherlands, United States, Belgium, France
ExCellThera inc.
Fred Hutchinson Cancer Center

Active, not recruiting

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

High Risk Hematological Malignancy | Cord Blood Transplant

United States, Netherlands
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
Vifor Pharma

Completed

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Chronic Heart Failure | Iron Deficiency

Netherlands
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
Henrik Endeman
Roche Diagnostics

Recruiting

The Value of Repeated BIOMarker Measurements During an SBT to Predict EXtubation Failure in ICU Patients (BIOMEXIC)

Weaning Failure | Mechanical Ventilation | Extubation Failure | Spontaneous Breathing Trial

Netherlands
UMC Utrecht
University Medical Center Groningen; Erasmus Medical Center; Catharina Ziekenhuis... and other collaborators

Unknown

Pheno- & Genotyping POF (WHO III)

Premature Ovarian Failure (POF) | Incipient Ovarian Failure | Poor Response After Ovarian Hyperstimulation | Early Menopause | Hypergonadotropic Amenorrhea

Netherlands
Sanofi

Completed

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

Hematopoietic Neoplasm

United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom

Clinical Trials on Bone Marrow Failure Disorders in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations